韩国生物制药巨头Celltrion近日宣布,欧盟委员会(EC)已批准Yuflyma(CT-P17,阿达木单抗生物类似药),该药是艾伯维(AbbVie)超重磅产品Humira(修美乐,通用名:adalimumab,阿达木单抗)的生物类似药。此次批准,涵盖治疗多种慢性炎症性疾病的所有预期13个适应症。 值得一提的是,Yuflyma是第一款高浓度、低容量、无枸橘酸...
2021年2月,欧盟委员会(EC)批准Yuflyma(CT-P17,阿达木单抗生物类似药),该药是艾伯维(AbbVie)超重磅产品Humira(修美乐,通用名:adalimumab,阿达木单抗)的生物类似药。 Yuflyma是第一款高浓度、低容量、无枸橘酸盐配方的阿达木单抗生物类似药。 Yuflyma配备29G针头、无乳胶设备,保质期可达24个月(2-8℃)。在...
Yuflyma(CT-P17)Adalimumab(阿达木单抗)是艾伯维(AbbVie)的Humira(ada […] Yuflyma(CT-P17)Adalimumab(阿达木单抗)是艾伯维(AbbVie)的Humira(adalimumab)修美乐(阿达木单抗)的生物类似药。在欧洲地区,Humira已于2018年10月16日失去专利保护,已有多款生物类似药上市销售。 2021年02月16日 韩国Celltrion生物制...
Pronunciation: yoo-fly’-mah Generic name: adalimumab-aaty Dosage forms: Yuflyma Auto-injector (40 mg/0.4mL), Yuflyma Prefilled Syringe with Safety Guard Injection (40 mg/0.4 mL), ... show all 3 dosage forms Drug class: TNF alfa inhibitors...
In May 2023, FDA approved Yuflyma [1], the ninth biosimilar for Adalimumab (Humira), to treat various inflammatory diseases including juvenile idiopathic arthritis (JIA), hidradeni-tis suppurativa, Crohn's disease (CD), plaque psoriasis (PP), ankylosing spondylitis (AnS), rheumatoid arthritis (...
Celltrion USA announced the launch of Yuflyma® (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar, providing an alternative option for patients. Yuflyma is indicated for the treatment of eight conditions, including ...
Celltrion, a Korean biopharmaceutical giant, said it has launched a 20-mg dosage formulation of its biosimilar Yuflyma (adalimumab) to treat autoimmune diseases in pediatric patients in the U.S.Yuflyma 20mg is the same high-concentration (100mg/mL) formu
Celltrion said Yuflyma (ingredient: adalimumab), a biosimilar referencing Humira, has been included in the formulary of one of the top three pharmacy benefit managers (PBMs) in the U.S. The three largest PBMs in the U.S., which include CVS Health, Express Scripts, and Optum, collectively...
Celltrion USA has received approval from the US Food and Drug Administration (FDA) for Yuflyma (adalimumab-aaty) for multiple indications.
韩国生物制药巨头Celltrion近日宣布,欧盟委员会(EC)已批准Yuflyma(CT-P17,阿达木单抗生物类似药),该药是艾伯维(AbbVie)超重磅产品Humira(修美乐,通用名:adalimumab,阿达木单抗)的生物类似药。此次批准,涵盖治疗多种慢性炎症性疾病的所有预期13个适应症。